# Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up

> **NCT05316077** · — · UNKNOWN · sponsor: **Guerbet** · enrollment: 50 (estimated)

## Conditions studied

- Oncology

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05316077
- **Lead sponsor:** Guerbet
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-30
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05316077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05316077, "Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05316077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*